Cargando…

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by multiple cellular and molecular dysfunctions of the innate and adaptive immunity. Cytotoxic function of NK cells is compromised in patients with SLE. Herein, we characterized the phenotypic alterations of SLE NK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humbel, Morgane, Bellanger, Florence, Fluder, Natalia, Horisberger, Alice, Suffiotti, Madeleine, Fenwick, Craig, Ribi, Camillo, Comte, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019934/ https://www.ncbi.nlm.nih.gov/pubmed/33828555 http://dx.doi.org/10.3389/fimmu.2021.645478

Ejemplares similares

Measurement of circulating CD21(−)CD27(−) B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers
por: Horisberger, Alice, et al.
Publicado: (2022)

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus
por: Humbel, Morgane, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on SLE: beyond the risk of infection
por: Horisberger, Alice, et al.
Publicado: (2020)

Innate Lymphoid Cells in Autoimmune Diseases
por: Clottu, Aurelie S., et al.
Publicado: (2022)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
por: Vaxman, I., et al.
Publicado: (2022)

Elotuzumab for multiple myeloma
Publicado: (2022)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
por: Decimoni, Tassia Cristina, et al.
Publicado: (2023)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Worse cardiovascular and renal outcome in male SLE patients
por: Mihailovic, Jelena, et al.
Publicado: (2023)

Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Antibodies to Chlamydia trachomatis and reproductive health issues in women with SLE: a case–control study
por: Santos, Alba, et al.
Publicado: (2018)

Mechanisms of Action and Clinical Development of Elotuzumab
por: Ritchie, David, et al.
Publicado: (2017)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
por: Viola, Domenico, et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study
por: Horisberger, Alice, et al.
Publicado: (2019)

Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis
por: Friebus-Kardash, Justa, et al.
Publicado: (2019)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
por: Obeid, Michel, et al.
Publicado: (2022)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
por: Crickx, Etienne, et al.
Publicado: (2021)

CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
por: Noto, Alessandra, et al.
Publicado: (2022)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings
por: Ghous, Ghulam, et al.
Publicado: (2020)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Management of Beta-Lactam Antibiotics Allergy: A Real-Life Study
por: Iuliano, Sarah, et al.
Publicado: (2022)

L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells
por: Jones Buie, Joy N, et al.
Publicado: (2019)

Hepatic irradiation persistently eliminates liver resident NK cells
por: Nakano, Ryosuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b8a4lt97b3jpkcg1893htphar4